Rafferty Asset Management
DFTX

Rafferty Asset Management’s Definium Therapeutics DFTX Stock Holding History

Rafferty Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,885
Closed -$253K – 1115
2025
Q4 		$253K Buy
18,885
+6,210
+49% +$76.8K ﹤0.01% 1030
2025
Q3 		$149K Buy
+12,675
New +$118K ﹤0.01% 1086
2025
Q2 		– Sell
-13,773
Closed -$80.6K – 1095
2025
Q1 		$80.6K Buy
+13,773
New +$98.6K ﹤0.01% 1051
2024
Q4 		– Sell
-18,658
Closed -$106K – 1163
2024
Q3 		$106K Buy
18,658
+1,359
+8% +$9.45K ﹤0.01% 1127
2024
Q2 		$125K Buy
+17,299
New +$151K ﹤0.01% 1156

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rafferty Asset Management's DFTX Position: Q1 2026 in Review

Rafferty Asset Management sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 18,885 shares — an estimated $253K sold.

Rafferty Asset Management first reported a position in DFTX in Q2 2024 and held it in 5 quarters. The position peaked at $253K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Rafferty Asset Management reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 18,885 Definium Therapeutics shares in Q1 2026, an estimated $253K.
  • Rafferty Asset Management first reported a position in Definium Therapeutics in Q2 2024 and held it in 5 quarters.
  • Rafferty Asset Management's Definium Therapeutics position peaked at $253K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.